Sort by Year





























Muchiri RN, Kibitel J, Redick MA, van Breemen RB. Advances in magnetic microbead affinity selection screening: Discovery of natural ligands to the SARS-CoV-2 spike protein. J. Am. Soc. Mass Spectrom. 2022; 33(1):181-188. doi: 10.1021/jasms.1c00318

van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG. Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. J. Nat. Prod. 2022; 85:176-184. doi: 10.1021/acs.jnatprod.1c00946

Elkhadragy L, Khabbaz RC, Muchiri RN, Totura WM, Samuelson JP, Whiteley HE, van Breemen RB, Lokken RP, Gaba RC. Pharmacokinetics and early tumor response to conventional transarterial chemoembolization with sorafenib and doxorubicin in a VX2 rabbit tumor model. J. Vasc. Interv. Radiol. 2022; 33:1213-1221.e5. doi: 10.1016/j.jvir.2022.07.011.

Rebiai R, Rue E, Zaldua S, Nguyen D, Scesa G, Jastrzebski M, Foster R, Wang B, Jiang X, Tai L, Brady ST, van Breemen R, Givogri MI, Sands MS, Bongarzone ER. CRISPR-Cas9 Knock-In of T513M and G41S mutations in the murine β-galactosyl-ceramidase gene re-capitulates early-onset and adult-onset forms of Krabbe disease. Front. Mol. Neurosci. 2022 May 10;15:896314. doi: 10.3389/fnmol.2022.896314

Feinstein DL, Hafner J, van Breemen R, Rubinstein I. Inhaled synthetic cannabinoids laced with long-acting rodenticides: A clear and present worldwide danger. Toxicol. Commun. 2022; 6(1):28-29. doi: 10.1080/24734306.2022.2025690

Reiter CR, Rebiai R, Kwak A, Marshall J, Wozniak D, Scesa G, Nguyen D, Rue E, Pathmasiri C, Pijewski R, van Breemen R, Cologna S, Crocker SJ, Givogri MI, Bongarzone ER. The pathogenic sphingolipid psychosine is secreted in extracellular vesicles in the brain of a mouse model of Krabbe disease. ASN Neuro. 2022 Jan-Dec;14:17590914221087817. doi: 10.1177/17590914221087817

Gaba RC, Khabbaz RC, Muchiri RN, Morrison JD, Elkhadragy L, Totura WM, Samuelson JP, Whiteley HE, Deaton RL, Nguyen PL, Sverdlov M, Johnson JJ, van Breemen RB, Lokken RP. Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. Drug Deliv. Transl. Res. 2022; 12(5):1105-1117. doi: 10.1007/s13346-021-00985-8